None

Proof of added benefit of apixaban in hip replacement

The clot-inhibiting drug apixaban (trade name: Eliquis) was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint. In an early benefit ass...

Apixaban Approved: Now Which Anticoagulant to Use?

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients. Expert...

Case building for long-term dabigatran or apixaban to treat VTE

New targeted anticoagulants such as dabigatran and apixaban might be effective options for the extended treatment of venous thromboembolism (VTE), industry-funded research in this week's New England...

ESC: Kidneys Not an Issue for Apixaban (CME/CE)

MUNICH (MedPage Today) -- The novel anticoagulant apixaban is better than warfarin at preventing stroke and reducing mortality independent of renal function, a secondary analysis of the ARISTOTLE tria...

U.S. FDA Approves ELIQUIS® (apixaban)

Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA approved ELIQUIS® (apixaban)...

FDA Wants More Apixaban Data

(MedPage Today) -- The FDA said Monday that it needs more data before it can approve apixaban, an oral factor Xa inhibitor, for prevention of stroke in patients with nonvalvular atrial fibrillation.

Apixaban offers minor added benefit for adult patients after hip replacement

The clot-inhibiting drug apixaban was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint.

Apixaban Wins Long-Awaited Nod from FDA

(MedPage Today) -- SILVER SPRING, Md. -- The FDA has approved the oral anticoagulant drug apixaban (Eliquis) to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.

Following major orthopaedic surgery, guidelines usually recommend continued thromboprophylaxis after hospitalisation. The availability of an effective oral anticoagulant with an acceptable safety prof...

Apixaban in Patients with Atrial Fibrillation.

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K an...

More light at the end of the tunnel - apixaban in atrial fibrillation.

Introduction: Subjects with atrial fibrillation are at risk of thromboembolic events. The vitamin K antagonists (e.g., warfarin) are useful at preventing coagulation in atrial fibrillation, but are di...

Apixaban: first global approval.

Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders. Apixaban has...

Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Apixaban (Eliquis™) is an orally active and selective direct inhibitor of factor Xa indicated for twice-daily use in the EU for the prevention of venous thromboembolism (VTE) in adults who have had...